Ensysce Biosciences, Inc.
8-K
March 30, 2026
Key Highlights
- Active search for a buyer or strategic partner
- Focus on proprietary abuse-deterrent opioid technology
- Management stability prioritized by the board to facilitate potential sale
Read Analysis
🤖 AI Generated